Biotech Values

[DewDiligence]

EYPT licenses drug for use with Durasert implant in AMD/DR/RPO:

https://www.globenewswire.com/news-release/2020/02/03/1979116/0/en/EyePoint-Pharmaceuticals-Signs-Exclusive-License-Agreement-with-Equinox-Science-to-Develop-Tyrosine-Kinase-Inhibitor-Vorolanib-for-the-Treatment-of-Wet-AMD-Diabetic-Retinopathy-and.html

Even if this works out, it could be a tough sell insofar as marketed drugs for back-of-the-eye diseases require dosing as little as three times per year.